Patricia Ann Thompson

US Patent:

8329636, Dec 11, 2012

Filed:

May 14, 2010

Appl. No.:

12/780592

Inventors:

Eugene Gerner - Tucson AZ, US
Jason A. Zell - Dana Point CA, US
Christine McLaren - Irvine CA, US
Frank Meyskens - Irvine CA, US
Hoda Anton-Culver - Irvine CA, US
Patricia A. Thompson - Tucson AZ, US

Assignee:

Arizona Board of Regents on Behalf of University of Arizona - Tucson AZ
The Regents of the University of California, a California Corporation - Oakland CA

International Classification:

A01N 61/00

US Classification:

514 1

Abstract:

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.

US Patent:

20130164751, Jun 27, 2013

Filed:

Dec 10, 2012

Appl. No.:

13/709753

Inventors:

Arizona Board of Regents on Behalf of University o - Tucson AZ, US
The Regents of the University of California, a Cal - Oakland CA, US
Christine E. MCLAREN - Irvine CA, US
Hoda ANTON-CULVER - Irvine CA, US
Patricia A. THOMPSON - Tucson AZ, US

Assignee:

The Regents of the University of California, a California Corporation - Oakland CA
Arizona Board of Regents on Behalf of University of Arizona - Tucson AZ

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.

US Patent:

20170362658, Dec 21, 2017

Filed:

Jun 18, 2014

Appl. No.:

15/319857

Inventors:

- Tucson AZ, US
Patricia THOMPSON - Tucson AZ, US
Tracy BROOKS - Oxford MS, US
Jenaro GARCIA-HUIDOBRO - Tucson AZ, US

International Classification:

C12Q 1/68
A61K 31/192
A61K 31/198

Abstract:

The present invention provides methods and kits a) for preventing and/or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection.

Author:

Patricia E. Thompson

ISBN #:

0803600631

Author:

Patricia E. Thompson

ISBN #:

0803602820

Author:

Patricia J. Thompson

ISBN #:

0026750600

Author:

Patricia J. Thompson

ISBN #:

0064535126

Author:

Patricia J. Thompson

ISBN #:

0070484376

Author:

Patricia J. Thompson

ISBN #:

0070484384

Author:

Patricia J. Thompson

ISBN #:

0820437492

Author:

Patricia J. Thompson

ISBN #:

0820457825